![Aman Kant](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Aman Kant is the founder of Invea Therapeutics, Inc., founded in 2021, and holds the title of President since 2025.
Former job includes Chief Business Officer at InveniAI LLC from 2017 to 2025.
Education includes undergraduate studies at Jaypee University of Information Technology.
| Bedrijven | Functie | Begin |
|---|---|---|
Invea Therapeutics, Inc.
 Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs | Oprichter | 20-10-2021 |
| Bedrijven | Functie | Einde |
|---|---|---|
Inveniai LLC
 Inveniai LLC Information Technology ServicesTechnology Services InveniAI LLC applies artificial intelligence and machine learning to accelerate drug discovery and development, focusing on diseases with unmet medical needs. The private company is based in Guilford, CT. The company leverages its proprietary AI platform, AlphaMeld®, to integrate scientific, medical, chemical, and biological data for generating hypotheses and prioritizing biological targets and treatment modalities. AlphaMeld® is used to decode complex pathways, such as the gut-brain axis and inflammasome pathways, to develop therapies for chronic inflammatory gastrointestinal diseases like irritable bowel syndrome and inflammatory bowel disease, with the goal of improving localized efficacy and reducing systemic side effects. InveniAI also offers ChatAlphaMeld, a generative AI assistant that supports literature review, predictive analytics, and clinical trial design while maintaining data privacy and content validation. The company collaborates with pharmaceutical partners and has participated in numerous biopharma collaborations. The CEO of the company is Krishnan Nandabalan. | Corporate Officer/Principal | 01-10-2025 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 3 |
|---|---|
Jaypee University of Information Technology
 Jaypee University of Information Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs | Health Technology |
Inveniai LLC
Inveniai LLC Information Technology ServicesTechnology Services InveniAI LLC applies artificial intelligence and machine learning to accelerate drug discovery and development, focusing on diseases with unmet medical needs. The private company is based in Guilford, CT. The company leverages its proprietary AI platform, AlphaMeld®, to integrate scientific, medical, chemical, and biological data for generating hypotheses and prioritizing biological targets and treatment modalities. AlphaMeld® is used to decode complex pathways, such as the gut-brain axis and inflammasome pathways, to develop therapies for chronic inflammatory gastrointestinal diseases like irritable bowel syndrome and inflammatory bowel disease, with the goal of improving localized efficacy and reducing systemic side effects. InveniAI also offers ChatAlphaMeld, a generative AI assistant that supports literature review, predictive analytics, and clinical trial design while maintaining data privacy and content validation. The company collaborates with pharmaceutical partners and has participated in numerous biopharma collaborations. The CEO of the company is Krishnan Nandabalan. | Technology Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau
Kies MarketScreener 
